Puma Biotechnology, Inc. (PBYI)

2.6500 -0.0300 (-1.12%) At close: 04:00PM EDT

Puma Biotechnology, Inc.

10880 Wilshire Boulevard
Suite 2150
Los Angeles, CA 90024
United States
424 248 6500
https://www.pumabiotechnology.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 192

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Alan H. Auerbach	Founder, Chairman, Pres, CEO & Sec.	1.74M	N/A	1970
Mr. Maximo F. Nougues	CFO & Principal Accounting Officer	781.47k	N/A	1969
Dr. Alvin F. Wong Pharm.d.	Chief Scientific Officer	809.69k	N/A	1953
Mr. Douglas Hunt B.Sc., FRAPS	Sr. VP of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law	632.65k	N/A	1965
Mr. Jeffrey Jerome Ludwig	Chief Commercial Officer	916.85k	N/A	1966
Mr. Mariann Ohanesian	Sr. Director of Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Corporate Governance

Puma Biotechnology, Inc.’s ISS Governance QualityScore as of September 1, 2023 is 5. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 3; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.